Patent 8461393 was granted and assigned to United Therapeutics on June, 2013 by the United States Patent and Trademark Office.
The compound according to Formula I is an intermediate in the synthesis of prostacylin analogs. The present invention provides an efficient method for synthesizing a Formula I compound.